Histone deacetylase in chronic lymphocytic leukemia.

Abstract:

BACKGROUND:Elevated histone deacetylase (HDAC) isoenzyme levels have been described in patients with carcinomas and leukemias. HDAC inhibitors (HDACi) have shown promise in the treatment of carcinomas and are currently under intense research. To make better use of HDACi in treating chronic lymphocytic leukemia (CLL), HDAC isoenzyme levels were studied. METHODS:Quantitative reverse transcriptase polymerase chain reaction for HDAC isoenzyme was measured in 32 patients with CLL and compared with 17 normal volunteer controls. ZAP-70, CD38 and CD44 were also assayed and correlated to HDAC isoenzyme levels. RESULTS:The results showed: (1) HDAC isoenzyme levels in CLL were significantly increased in class I including HDAC1 and HDAC3, in class II including HADC6, HDAC7, HDAC9 and HDAC10, and in class III including SIRT1 and SIRT6; (2) higher expression of HDAC isoenzyme levels was found in ZAP-70+ compared to ZAP-70- patients, and CD44 expression levels were correlated with HDAC isoenzyme expression levels in the majority of HDAC classes. CONCLUSIONS:These results suggest: (1) in CLL, elevated HDAC isoenzyme activity is not restricted to one class, and therefore, HDACi therapy may need to be directed to more than one specific class of HDAC; (2) higher HDAC expression activity may indicate a poor prognosis and more advanced disease stage (through indirect evidence), since higher values were found in patients with ZAP-70+ and higher CD44 expression levels.

journal_name

Oncology

journal_title

Oncology

authors

Wang JC,Kafeel MI,Avezbakiyev B,Chen C,Sun Y,Rathnasabapathy C,Kalavar M,He Z,Burton J,Lichter S

doi

10.1159/000334577

subject

Has Abstract

pub_date

2011-01-01 00:00:00

pages

325-9

issue

5-6

eissn

0030-2414

issn

1423-0232

pii

000334577

journal_volume

81

pub_type

杂志文章

相关文献

ONCOLOGY文献大全
  • Primary gastric non-Hodgkin's lymphoma localized to the gastric wall: no adjuvant treatment following radical surgery.

    abstract::The paper presents the experience with watch-and-wait policy following radical surgery in 25 patients with primary gastric non-Hodgkin's (NH) lymphoma localized to the gastric wall. The median follow-up is at the moment 40 months (range 18-85). Only 3/25 patients have relapsed (during the first year of the follow-up) ...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000227347

    authors: Jelić S,Kovcin V,Jovanović V,Oprić M,Milanović N

    更新日期:1994-05-01 00:00:00

  • Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes.

    abstract:OBJECTIVES:The aim of this study was to identify biomarkers for predicting the efficacy of docetaxel, cisplatin, and S-1 (DCS) therapy for advanced gastric cancer using microarrays of biopsy specimens before chemotherapy. METHODS:Nineteen samples were taken from 19 patients with unresectable metastatic gastric cancer ...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000464329

    authors: Kitamura S,Tanahashi T,Aoyagi E,Nakagawa T,Okamoto K,Kimura T,Miyamoto H,Mitsui Y,Rokutan K,Muguruma N,Takayama T

    更新日期:2017-01-01 00:00:00

  • Synchronous Hodgkin's disease and gastric adenocarcinoma.

    abstract:BACKGROUND:Adenocarcinoma is the most frequent pathological type of stomach cancer. Hodgkin's lymphoma is a lymphoproliferative disease arising from lymphoid tissue which is characterized by Reed-Sternberg cells. Synchronous occurrence of these two malignancies has not been reported in the English literature so far. C...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000136799

    authors: Comez G,Pehlivan Y,Kalender ME,Sevinc A,Sari I,Camci C

    更新日期:2007-01-01 00:00:00

  • Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients.

    abstract::The cytochrome P450 CYP2D6 is a polymorphic drug-metabolizing enzyme that is involved in the metabolism of several drugs and xenobiotics. Several independent studies indicate that the CYP2D6 metabolic status is a secondary factor in the risk of developing lung cancer, with individuals with high activity being at incre...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000055354

    authors: Agúndez JA,Gallardo L,Ledesma MC,Lozano L,Rodriguez-Lescure A,Pontes JC,Iglesias-Moreno MC,Poch J,Ladero JM,Benítez J

    更新日期:2001-01-01 00:00:00

  • Recombinant human granulocyte colony-stimulating factor in the management of cancer patients: five years on.

    abstract::Recombinant human granulocyte colony-stimulating factor (G-CSF) has been used worldwide in cancer patients for over 1 year, and (only 5 years from the first publication on the clinical use of this growth factor) experience is rapidly accumulating in many oncological situations. Several randomized studies have confirme...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000227333

    authors: Bronchud MH

    更新日期:1994-03-01 00:00:00

  • Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).

    abstract:OBJECTIVE:This phase II study examined the efficacy and safety of alternating regimens of mFOLFOX6 and FOLFIRI as a first-line treatment for unresectable or metastatic colorectal cancer. PATIENTS AND METHODS:Forty-eight patients were enrolled in this study. Patients received an alternating regimen of 4 cycles of mFOLF...

    journal_title:Oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1159/000346690

    authors: Oki E,Emi Y,Akagi Y,Tokunaga S,Sadanaga N,Tanaka T,Ogata Y,Saeki H,Kakeji Y,Baba H,Nishimaki T,Natsugoe S,Shirouzu K,Maehara Y,Kyushu Study Group of Clinical Cancer.

    更新日期:2013-01-01 00:00:00

  • Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer.

    abstract:OBJECTIVE:We evaluated the efficacy and safety of bolus 5-fluorouracil (5-FU) and leucovorin combined with weekly paclitaxel (FLTAX) in advanced gastric cancer (GC) patients. METHODS:Patients with untreated stage IV GC received paclitaxel 80 mg/m(2) as a 1-hour infusion, followed by 5-FU 600 mg/m(2) as a bolus infusio...

    journal_title:Oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1159/000334462

    authors: Matsubara J,Shimada Y,Kato K,Nagai Y,Iwasa S,Nakajima TE,Hamaguchi T,Yamada Y,Takagi S,Kobayashi K,Yoshioka A,Nakayama N,Tsuji A

    更新日期:2011-01-01 00:00:00

  • Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.

    abstract::In the 2010 version of the Japan Society of Hepatology (JSH) consensus-based treatment algorithm for the management of hepatocellular carcinoma (HCC), transarterial chemoembolization (TACE) failure/refractoriness was defined assuming the use of superselective lipiodol TACE, which has been widely used worldwide and par...

    journal_title:Oncology

    pub_type: 共识发展会议,杂志文章,实务指引,评审

    doi:10.1159/000368142

    authors: Kudo M,Matsui O,Izumi N,Kadoya M,Okusaka T,Miyayama S,Yamakado K,Tsuchiya K,Ueshima K,Hiraoka A,Ikeda M,Ogasawara S,Yamashita T,Minami T,Liver Cancer Study Group of Japan.

    更新日期:2014-01-01 00:00:00

  • Clinical Impact of Aprepitant in Patients Receiving High-Dose Chemotherapy prior to Autologous Peripheral Blood Stem Cell Transplantation: A Cost-Effectiveness Analysis.

    abstract:OBJECTIVE:To evaluate the clinical and cost benefits of the administration of aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) during high-dose chemotherapy (HDCT). METHODS:We retrospectively reviewed the charts of patients who received HDCT at our institution between January 2009 and ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000479032

    authors: Nakamura A,Kojima Y,Miyazawa K,Matsumoto S,Iida H,Nagai H

    更新日期:2017-01-01 00:00:00

  • Effects of cytotoxic chemotherapy on ovarian and adrenal steroidogenesis in pre-menopausal breast cancer patients.

    abstract::Many patients on cytotoxic chemotherapy show reduced frequency of menstrual bleeding due to a reduction in ovarian follicular activity. The endocrine perturbations related to these changed menstrual patterns were studied in detail. Nineteen regularly menstruating patients with primary breast cancer were given either c...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226930

    authors: Dowsett M,Richner J

    更新日期:1991-01-01 00:00:00

  • Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?

    abstract:BACKGROUND:Whether recurrence after surgery and primary metastatic pancreatic cancer should be included in the same category when conducting gemcitabine-based clinical trials remains controversial. OBJECTIVE:To clarify the outcomes of recurrent and metastatic pancreatic cancers. METHODS:326 patients who received gemc...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000236022

    authors: Hashimoto K,Ueno H,Ikeda M,Kojima Y,Hagihara A,Kondo S,Morizane C,Okusaka T

    更新日期:2009-01-01 00:00:00

  • Treatment of colorectal cancer with and without bevacizumab: a phase III study.

    abstract:OBJECTIVE:The objective of this phase III trial was to compare chemotherapy combined with bevacizumab versus chemotherapy alone in the treatment of patients with advanced colorectal cancer. METHODS:From September 2004 till September 2008, 222 treatment-naive patients were enrolled and divided into 2 arms: 114 arm A pa...

    journal_title:Oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1159/000320520

    authors: Stathopoulos GP,Batziou C,Trafalis D,Koutantos J,Batzios S,Stathopoulos J,Legakis J,Armakolas A

    更新日期:2010-01-01 00:00:00

  • Chemoradiotherapy alone as the standard treatment of epidermoid esophageal carcinoma.

    abstract:OBJECTIVES:Surgery has traditionally been the treatment of choice for patients with potentially resectable esophageal carcinoma. Recently, however, definitive chemoradiotherapy (CRT) has been suggested as a preferred treatment modality. In this study, CRT results with or without surgery are compared. METHODS:A total o...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000333448

    authors: Salek R,Tabrizi FV,Bezenjani SE,Saedi HS,Ashkiki MH,Hosainzadeh SM,Mohtashami S

    更新日期:2011-01-01 00:00:00

  • Identification of Aneuploid Circulating Tumor Cells in Soft-Tissue Sarcoma Patients: A Pilot Study.

    abstract:BACKGROUND:Circulating tumor cells (CTCs) have been identified and shown to have prognostic and predictive roles in several types of carcinoma. More recently, aneuploid CTCs have become subject of a growing interest, as aneuploidy is considered a hallmark of cancer often associated with poor prognosis. Here, we aimed t...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000509326

    authors: Napolitano A,Minelli A,Santini D,Tonini G,Vincenzi B

    更新日期:2020-01-01 00:00:00

  • Cytogenetic testing of mutagenic and radioprotective effects of mesna.

    abstract::The effects of mesna (sodium 2-mercaptoethane-sulfonate) on the frequency of sister chromatid exchange (SCE) and chromosomal aberrations were studied in PHA-stimulated lymphocytes in vitro. Our data give no evidence for either an increase of SCE or chromosomal aberrations and, thus, do not suggest a mutagenic or cance...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000225745

    authors: Becher R,Kakati S,Gibas Z,Sandberg AA

    更新日期:1983-01-01 00:00:00

  • Latent coagulation disorders evaluated by the assay of plasma thrombin-antithrombin III complexes in a large series of 'solid tumours'.

    abstract::Coagulation disorders are frequently detected in patients affected by different tumours even though clinical symptoms occur in a very small percentage of such subjects. Coagulation processes are probably involved in the mechanism of metastatic spread. We assayed the plasma levels of thrombin-antithrombin III (TAT) com...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227086

    authors: Bartoloni C,Guidi L,Tricerri A,Patriarca F,Pili R,Cursi F,Canetta M,Cappelli A,Vangeli M,Salvati F

    更新日期:1992-01-01 00:00:00

  • Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival.

    abstract:OBJECTIVES:Anaplastic oligodendrogliomas (AO) are uncommon primary brain tumors whose natural history, prognosis, and optimal management are not yet fully understood. However, they are associated with a better prognosis and response to multimodality therapy based on specific molecular changes. In this multicenter retro...

    journal_title:Oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1159/000074479

    authors: Puduvalli VK,Hashmi M,McAllister LD,Levin VA,Hess KR,Prados M,Jaeckle KA,Yung WK,Buys SS,Bruner JM,Townsend JJ,Davis R,Sawaya R,Kyritsis AP

    更新日期:2003-01-01 00:00:00

  • Antiemetic efficacy of moderately high-dose metoclopramide in patients receiving varying doses of cisplatin. Controlled comparison with a combination of methylprednisolone and metoclopramide.

    abstract::In 29 patients (48 courses of chemotherapy), a randomized double-blind crossover study was undertaken to establish the antiemetic effectiveness of a combination of metoclopramide at a moderately high dose (5 mg/kg body weight) with 1 g methylprednisolone (treatment A) as compared with metoclopramide monotherapy (5 mg/...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1159/000226063

    authors: Ell C,König HJ,Brockmann P,Domschke S,Domschke W

    更新日期:1985-01-01 00:00:00

  • Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer.

    abstract:OBJECTIVES:Primary chemoradiotherapy for locally advanced pancreatic cancer (LAPC) may improve local control, curative resection rate and long-term survival. We performed a phase II study to evaluate toxicity and activity of primary radiation therapy and concurrent chemotherapy with gemcitabine (GEM) twice weekly in pa...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000086993

    authors: Magnino A,Gatti M,Massucco P,Sperti E,Faggiuolo R,Regge D,Capussotti L,Gabriele P,Aglietta M

    更新日期:2005-01-01 00:00:00

  • Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer.

    abstract:BACKGROUND AND OBJECTIVES:Even though the pathological background contributes to lymph node metastasis, the biological characteristics of tumors have also gained wide attention. In this study, the expression of the cadherin-catenin complex and p53 was studied in early gastric cancer. Their correlation with lymph node m...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000012020

    authors: Xiangming C,Hokita S,Natsugoe S,Tanabe G,Baba M,Takao S,Kuroshima K,Aikou T

    更新日期:1999-01-01 00:00:00

  • Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.

    abstract::Methyl-CCNU (NSC-95441) was administered to patients with malignant melanoma in a split dose schedule. Nausea and vomiting were eliminated as clinical problems during therapy. Response rate to the drug seemed somewhat lower than the average of three previously reported disease-oriented phase II trials, though the diff...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000225178

    authors: Wittes RE,Hong WK,Gatchell L,Krakoff IH,Golbey RB

    更新日期:1977-01-01 00:00:00

  • Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.

    abstract:OBJECTIVES:18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for differentiating benign from malignant lesions, evaluating tumor stage, monitoring the response to therapy and detecting tumor recurrence in a variety of malignancies. Nevertheless, its use in patients with hepatocellular carcinoma (H...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000111715

    authors: Yoon KT,Kim JK,Kim DY,Ahn SH,Lee JD,Yun M,Rha SY,Chon CY,Han KH

    更新日期:2007-01-01 00:00:00

  • Assessment of quality of care in an oncology institute using information on patients' satisfaction.

    abstract:OBJECTIVE:To evaluate the feasibility of conducting a patient satisfaction survey in the oncology hospital setting, using a multidimensional patient satisfaction questionnaire to be completed at home. METHODS:Socio-demographic and clinical data were collected for 133 consecutive patients. Patients were asked to comple...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000055362

    authors: Brédart A,Razavi D,Robertson C,Didier F,Scaffidi E,Fonzo D,Autier P,de Haes JC

    更新日期:2001-01-01 00:00:00

  • Testicular seminoma: results of treatment at the Northern Israel Oncology Center.

    abstract::The survival, and the patterns and mechanisms of failure of 41 patients with pure testicular seminoma treated at the Northern Israel Oncology Center from 1968 to 1983 were analyzed. The actuarial 5-year survival of all patients was 85.4% and of stage I patients, 92.2%. Treatment failures were analyzed. The following c...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226341

    authors: Stein M,Steiner M,Koten A,Cohen Y,Robinson E

    更新日期:1986-01-01 00:00:00

  • Therapeutic management of stage I-II high-grade primary gastric lymphomas.

    abstract::The best treatment for primary gastric lymphomas (PGL) has not yet been defined. Eighty-three patients with stage I/II PGL are documented, focusing on prognostic factors, treatment-related morbidity and mortality, and therapeutic outcome. Chemotherapy improved survival in comparison to local treatments, i.e. gastrecto...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000011978

    authors: Ferreri AJ,Cordio S,Paro S,Ponzoni M,Freschi M,Veglia F,Villa E

    更新日期:1999-01-01 00:00:00

  • Plasma alpha-1-antitrypsin levels in early and late carcinoma of the cervix.

    abstract::Previous studies have demonstrated a rise in serum alpha-1-antitrypsin at advanced stages of malignancy. These, together with results of animal experiments with another anti-proteinase, aprotinin, have prompted studies of the plasma alpha-1-antitrypsin in the early stages of malignancy, using cervical carcinoma as a m...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000225093

    authors: Latner AL,Turner GA,Lamin MM

    更新日期:1976-01-01 00:00:00

  • Low-dose aminoglutethimide therapy without glucocorticoid administration. Clinical and hormonal findings.

    abstract::Eleven postmenopausal patients with advanced breast cancer were assessed for their response and endocrine changes to low-dose aminoglutethimide (250 mg twice a day) therapy without steroid administration. In 7 cases an objective response was registered; 1 patient had a stabilization of the disease lasting for 9 months...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227006

    authors: Kahán Z,Tóth I,Vecsernyés M

    更新日期:1992-01-01 00:00:00

  • Persistence of chromosomal aberrations in blood lymphocytes of testicular cancer patients. I. The effect of vinblastine, cisplatin and bleomycin adjuvant therapy.

    abstract::Chromosomal aberrations and sister chromatid exchanges were examined in 45 patients with nonseminomatous testicular cancer at different times after the termination of vinblastine, cisplatin and bleomycin (VPB) therapy and in 22 age-matched healthy men and untreated testicular cancer patients. After 36 months, the freq...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226859

    authors: Gundy S,Baki M,Bodrogi I,Czeizel A

    更新日期:1990-01-01 00:00:00

  • Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses.

    abstract:OBJECTIVES:Calcitriol, 1alpha,25-dihydroxyvitamin D(3) (1,25-D(3)) has potent antiproliferative effects and potentiates the antitumor activity of many other cytotoxic drugs. 1,25-D(3) plasma pharmacokinetic (PK) parameters associated with antitumor activity in experimental animal models are unknown. The objective of th...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000076336

    authors: Muindi JR,Modzelewski RA,Peng Y,Trump DL,Johnson CS

    更新日期:2004-01-01 00:00:00

  • Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice.

    abstract:BACKGROUND:Immuno-oncological (IO) therapies such as PD-1 and PD-L1 antibodies have been introduced in the treatment of advanced non-small cell lung cancer (NSCLC) since 2015 based on randomized trials showing unprecedented advantages in overall survival (OS) with hazard ratios (HRs) between 0.5 and 0.7. The impact of ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000500885

    authors: Faehling M,Kopp M,Schwenk B,Fallscheer S,Kramberg S,Eckert R

    更新日期:2019-01-01 00:00:00